Paper Details

  1. Home
  2. Paper Details

DFMO: targeted risk reduction therapy for colorectal neoplasia.

Author: GernerEugene W, LaukaitisChristina M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study explored the effectiveness of reducing intracellular polyamine levels to decrease colorectal cancer (CRC) risk. A combination of difluoromethylornithine (DFMO) and non-steroidal anti-inflammatory drugs (NSAIDs) showed a significant reduction in adenoma recurrence. However, the treatment group had a slightly higher rate of cardiovascular events compared to the placebo group, along with mild ototoxicity. Targeted therapy for high-risk individuals with CRC could potentially improve patient benefit while minimizing side effects.
Paper Details　
Original Abstract of the Article :
Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22122766

データ提供：米国国立医学図書館（NLM）

DFMO: Targeted Risk Reduction Therapy for Colorectal Neoplasia

This study explores the use of difluoromethylornithine (DFMO) as a targeted risk reduction therapy for colorectal neoplasia, a significant public health concern. The researchers conducted a Phase III trial to assess the efficacy and safety of DFMO in combination with sulindac for preventing the recurrence of colorectal adenomas. The study provides valuable insights into the potential of DFMO as a targeted therapy for reducing colorectal cancer risk.

DFMO: A Potential Weapon Against Colorectal Cancer

The study suggests that DFMO, in combination with sulindac, holds promise as a targeted therapy for reducing the risk of colorectal neoplasia. It's like finding a potent weapon in the desert of cancer research, offering a potentially effective approach to prevention. The study's findings provide valuable data for clinicians and researchers working to combat this devastating disease.

Navigating the Desert of Cancer Research

The research highlights the complexities of cancer prevention, comparing it to navigating a vast and challenging desert landscape. The study's findings provide a potential new route through this desert, offering hope for more effective prevention strategies. It's essential to acknowledge the need for further research to fully understand the efficacy and safety of DFMO as a targeted therapy for colorectal cancer.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the desert of cancer research, highlighting the potential of DFMO as a targeted therapy for reducing the risk of colorectal neoplasia. It's like finding a new source of water in a parched land, offering a potential solution to a critical health challenge. More research is needed to confirm its effectiveness and ensure its safe and sustainable use.

Date :
  1. Date Completed 2012-03-22
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22122766

DOI: Digital Object Identifier

NIHMS336997

Related Literature

Article Analysis
・Side Effects of sulindac
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.